Celgene (NASDAQ:CELG) has been a "core" position within the model 20-stock Biotech Forum portfolio for quite some time. Although the stock is more expensive than some other drug and biotech giants, no other large-cap name in this sector has a more visible revenue and earnings growth trajectory over the next 3-5 years and probably beyond. Every month, the company seems to give more confirmation of this. If there is a large-cap biotech holding that is more a "fire & forget" name in this area of the market, I am unaware of it. Let's take a look at the company's core growth drivers.
Established Growth Engines
Revlimid
